UBS initiated coverage on Harmony Biosciences Holdings Inc (HRMY) with a Buy rating and a $56 price target, citing strong growth potential for its narcolepsy drug Wakix and a promising pipeline of CNS assets. The firm expects Wakix to achieve $1.2 billion in peak sales, driven by increased narcolepsy diagnosis and the drug’s unique profile in the polypharmacy market.
Academy Sports and Outdoors (ASO) reported mixed quarterly earnings, missing revenue estimates but meeting earnings per share expectations. Despite meeting earnings, the company’s stock has been downgraded to a ‘Sell’ rating due to unfavorable earnings estimate revisions and a weak industry outlook. The company’s revenue performance and industry trends will be crucial factors to watch moving forward.
Air Products is poised for growth driven by strategic investments and productivity initiatives, but the company faces challenges from economic weakness in China and Europe. Despite these headwinds, Air Products remains a solid investment due to its dividend growth and commitment to shareholder returns.
Provident Industrial has successfully sold the third phase of its Gateway Logistics Park in El Paso, Texas, to EQT Exeter. The 345,394 square foot Building III features modern industrial space and strategic location, attracting companies focused on cross-border logistics and distribution. This sale reflects the growing demand for industrial real estate in El Paso driven by nearshoring and reshoring trends.
Woolpert has been chosen to provide on-call consulting services for Terre Haute Regional Airport, aiming to enhance infrastructure and amenities while preparing for future expansion. The five-year contract covers a range of architectural, engineering, and construction services, supporting the airport’s role as a vital economic hub for the region.
Newmont Corporation (NEM) has seen impressive share growth in recent months, fueled by strong earnings, higher gold prices, and strategic acquisitions. This article analyzes the company’s fundamentals, growth prospects, and potential risks to help investors determine if NEM is a good investment opportunity.
Roivant Sciences’ subsidiary, Pulmovant, has secured global rights to mosliciguat, an inhaled sGC activator for pulmonary hypertension (PH). Initial Phase 1b trial results show significant reductions in pulmonary vascular resistance, highlighting the potential of this therapy for PH-ILD patients.
US stock markets closed with a mixed performance, with the Nasdaq Composite gaining over 100 points, while the Dow Jones Industrial Average dipped slightly. Oil prices took a significant tumble, dropping over 4% due to a revised demand forecast from OPEC. Meanwhile, European markets closed lower and Asian markets closed mostly higher.
Boeing stock experienced a decline on Tuesday, driven by a six-month delay in a key production milestone for the 737 MAX. The company also announced its plans for a significant step towards developing a global quantum internet with the launch of its Q4S satellite in 2026. Despite these developments, Boeing delivered 40 commercial jets in August, exceeding last year’s figures.
Truist Securities initiated coverage on Longboard Pharmaceuticals, Inc. (LBPH) with a Buy rating and a $60 price target, citing its CNS-focused biotech platform and the potential of its lead drug bexicaserin to disrupt the epilepsy market. The analyst believes bexicaserin’s superior safety profile and comparable efficacy to current market leader Fintepla could lead to market share gains and market expansion.
